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Abstract
Rational—Nicotine use in schizophrenia has traditionally been explained as ‘self-medication’ of 
cognitive and/or nicotinic acetylcholinergic receptor (nAChR) abnormalities.
Objectives—We test this hypothesis in a neurodevelopmental rat model of schizophrenia that 
shows increased addiction behaviors including enhanced nicotine reinforcement and drug-seeking.
Methods—Nicotine transdermal patch (5 mg/kg/day vs. placebo × 10 days in adolescence or 
adulthood) effects on subsequent radial-arm maze learning (15 sessions) and frontal-cortical-
striatal nAChR densities (α4β2; [3H]-epibatidine binding) were examined in neonatal ventral 
hippocampal lesion (NVHL) and SHAM-operated rats.
Results—NVHL cognitive deficits were not differentially affected by nicotine history compared 
to SHAMs. Nicotine history produced minimal cognitive effects while increasing food–reward 
consumption on the maze, compounding with NVHL-induced overconsumption. Acute nicotine 
(0.5 mg/kg) delivered before the final maze sessions produced modest improvements in maze 
performance in rats with nicotine patch histories only, but not differentially so in NVHLs. 
Consistent with in vivo neuroimaging of β2 nAChR binding in schizophrenia smokers vs. non-
smokers and healthy controls, adult NVHLs showed 12% reductions in nAChR binding in MPFC 
(p<0.05) but not ventral striatum (<5% changes, p>.40), whereas nicotine history elevated 
nAChRs across both regions (>30%, p<0.001) without interacting with NVHLs. Adolescent vs. 
adult nicotine exposure did not alter nAChRs differentially.
Conclusions—Although replicating nicotine-induced up-regulation of nAChRs in human 
smokers and demonstrating NVHL validity in terms of schizophrenia-associated nAChR density 
patterns, these findings do not support hypotheses explaining increased nicotine use in 
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schizophrenia as reflecting illness-specific effects of nicotine to therapeutically alter cognition or 
nAChR densities.
INTRODUCTION
Nicotine addiction is the leading cause of premature death in the U.S. (Mokdad et al. 2004). 
It typically starts during adolescence (Chen and Millar 1998) afflicting about 20% of the 
general population, but 60% to 90% of people with schizophrenia (Dickerson et al. 2013) 
where smoking-related medical illness is responsible for the majority of all deaths 
(Callaghan et al. 2014). Nicotine addiction is also more severe in people with schizophrenia 
compared to non-mentally smokers, as they consume more cigarettes per day, extract more 
nicotine per cigarette, and are more refractory to nicotine cessation efforts (de Leon and 
Diaz 2005; Williams et al. 2005).
Psychiatric research has traditionally assumed nicotine use in schizophrenia represents self-
medication, assigning therapeutic value to nicotine (Dalack et al. 1998; Leonard et al. 2007). 
Genetic markers in schizophrenia have been associated with nicotinic acetylcholinergic 
receptor (nAChR) genes or function, and cognitive or electrophysiological endophenotypes 
of schizophrenia may be normalized by nicotine (Harris et al. 2004; Leonard et al. 2007; 
Potter et al. 2006; Smith et al. 2002). However, recent studies suggest that tobacco and/or 
nicotine have no differential cognitive performance effects in mentally ill vs. healthy 
subjects, (Esterlis et al. 2014; Hahn et al. 2013; Quisenaerts et al. 2014; Roh et al. 2014), 
and that chronic nicotine exposure may actually worsen psychiatric and cognitive 
trajectories (Cavazos-Rehg et al. 2014 (in press); Counotte et al. 2011; Ernst et al. 2001; 
McDermott et al. 2013; Mojtabai and Crum 2013; Taylor et al. 2014). Moreover, a long-
standing tradition of research on smoking and schizophrenia that endorses the self-
medication hypothesis as the standard view in the field, may have inadvertently promoted 
acceptance and positive attitudes about smoking in the minds of clinicians and patients, 
contributing to a treatment culture that insufficiently diagnoses and treats nicotine addiction 
in mentally ill people (Callaghan et al. 2014; Prochaska et al. 2013). In the middle of this 
debate stands the well-replicated, but still mysterious neurobiological finding that nAChRs 
are decreased in schizophrenia brains (Breese et al. 2000; D'Souza et al. 2012; Durany et al. 
2000; Esterlis et al. 2014; Freedman et al. 1995). The significance of this is unclear, 
particularly since schizophrenia patients consume high doses of nicotine, which should 
dose-dependently increase nAChR expression (Nguyen et al. 2004). Interpretations of this 
phenomenon as self-medication have proposed that patients use nicotine to up-regulate low 
nAChRs to ameliorate cognitive deficits (Breese et al. 2000; Durany et al. 2000).
Animal models allow experimental control and prospective testing of hypotheses about 
causal mechanisms linking nicotine use and mental illness in ways that are not ethical in 
human research. Such modeling is particularly important if it is considered that introducing 
chronic nicotine use may be more harmful than therapeutic, and that non-therapeutic 
mechanisms may be responsible for increased nicotine use in schizophrenia. No studies have 
examined nicotine's impact on cognition and nAChRs in animal models of schizophrenia 
that encompass increases in nicotine reinforcement and other addiction-related behaviors. 
Addressing this empirical gap, we used a widely studied schizophrenia model produced by 
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neonatal ventral hippocampal lesions (NVHL) in rats (Lipska et al. 1993). These lesions, 
directly impacting a small portion of total hippocampal volume, are introduced at a 
neurodevelopmental stage approximate to the 2nd to 3rd trimester of human development, 
when genetic and environmental factors are thought to initially conspire to alter 
hippocampal development in schizophrenia. NVHLs produce multiple behavioral, 
developmental, pharmacological and biological features of schizophrenia (see (Tseng et al. 
2009) for comprehensive review), that result in part from corruption of normal adolescent 
prefrontal cortical development and cortical-hippocampal connectivity. Key behavioral 
features of the model include post-adolescent onset of abnormal behaviors associated with 
dopaminergic tone (e.g. abnormal behavioral reactivity to novelty, stressors, and stimulant 
drugs) that are reducible with both typical and atypical neuroleptic agents. These symptoms 
emerge on top of negative (e.g. social deficits, loss of grooming) and cognitive symptoms 
(e.g. deficits in sensory gating, decision making, contextual working memory) that are 
detectible before adolescence, and are neuroleptic-resistant. NVHL rats also show increased 
self-administration of multiple drugs characteristically abused at high rates in schizophrenia 
patients including cocaine, alcohol and nicotine (Berg et al. 2011; Berg et al. 2013; 
Chambers and Self 2002). With respect to nicotine, NVHLs amplify the effects of 
experimenter-delivered nicotine injections to generate short and long-term behavioral 
sensitization (Berg and Chambers 2008). Similarly, NVHLs self-administer nicotine at 
greater rates compared to healthy rats across acquisition and maintenance stages, leading to 
greater nicotine-seeking behavior after nicotine access is removed (Berg et al. 2013).
This study examined nicotine's effects on subsequent cognition and nAChR expression in 
NVHL rats, to determine if nicotine has NVHL-specific effects in these domains. We used 
transdermal nicotine patch-exposure (5mg/kg/day × 10 days) previously shown to produce 
nicotine blood levels in rats of 60-70 ng/ml (Slawecki et al. 2005). This range is comparable 
to the upper extremes of ranges found in human smokers and patch users of 20-60 ng/ml 
(Benowitz et al. 2002; Fagerstrom and Hughes 2002) which accounts for rodent–to human 
dose equivalencies that require somewhat higher blood levels of the drug in the smaller 
species with faster metabolism (Matta et al. 2007). This exposure also produces nAChR up-
regulation, and bio-behavioral changes persisting from adolescence into adulthood (Nguyen 
et al. 2004; Slawecki et al. 2005). While two major classes of nAChRs, α7 and α4β2, are 
implicated in cognition and schizophrenia, we focused on α4β2 in this initial study because 
it is involved in diverse behavioral effects of nicotine, including cognitive and primary 
reinforcing effects (Picciotto et al. 1998) and is a key receptor target of interest for treating 
both nicotine addiction (e.g. with varenicline) and schizophrenia (Roh et al. 2014). 
Assessment of nAChRs across cortical-striatal regions implicated in schizophrenia and 
addiction (Chambers et al. 2013) employed [3H]-epibatidine radio-ligand binding 
commonly used to study α4β2 receptors in nicotine use (Nguyen et al. 2004) and 
schizophrenia (Breese et al. 2000). In cortical-striatal regions, α4β2 receptors represent 
>90% of epibatidine binding (Perry et al. 2002). For measuring cognition, we employed a 
Radial-Arm Maze (RAM) paradigm that is sensitive to NVHL-cognitive deficits (Chambers 
et al. 1996) and nicotine (Levin and Rose 1991). Our study design provided an animal model 
parallel to recent human neuroimaging work looking at nAChRs in human smokers with and 
without schizophrenia (Esterlis et al. 2014) while addressing these questions: 1) Are NVHL-
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cognitive deficits differentially altered after chronic nicotine and/or with acute doses 
compared to controls? 2) Do NVHL rats show differential baseline or nicotine-induced 
nAChR up-regulation 3) Do nicotine-induced nAChR changes reflect age, NVHL, or 
nicotine-related differences in cognition?
MATERIALS AND METHODS
Subjects, Surgery and Experimental Design
Pregnant Sprague-Dawley rats (14 days gestation) arriving from Harlan (Indianapolis) were 
housed under standard conditions. Litters were culled to males only on Post-natal Day (PD) 
4. On PD 7, pups (16-18g) were randomized to neonatal lesion vs. SHAM surgery to keep 
litters approximately balanced by lesion status, but with an overabundance of lesion over 
SHAM surgeries (ratio of lesion:sham rats approximately 1.2 per litter) to anticipate attrition 
due to poorly placed lesions. Ibotenate was infused into ventral hippocampi bilaterally in 
NVHLs while SHAMs only received vehicle, as described in elsewhere (Chambers and 
Lipska 2011). Post-operatively, pups were returned to their litters and left undisturbed until 
weaning (PD 21). Thereafter, subjects were pair-housed (by lesion) until patch exposure, 
then individually housed. As per the overall experimental design (Figure 1A), NVHL and 
SHAM rats were randomly assigned into balanced cohorts to undergo nicotine (NIC) vs. 
placebo (PBO) patch exposure for 10 days in adolescence (PD 35-44) or adulthood (PD 
60-69). One day afterward, rats entered either the cognitive arm of the study (i.e. 15 sessions 
of RAM testing with acute nicotine delivered to all rats before sessions 13-15), or the 
binding arm (i.e. sacrifice for nAChR binding in cortical-striatal tissue samples). Procedures 
complied with Guide for the Care and Use of Laboratory Animals and Indiana University 
IACUC.
Nicotine
Transdermal nicotine patches (Nicoderm CQ, 7 mg, Smith-Kline Beecham: Pittsburgh, PA) 
vs. placebo (PBO) patches (medical adhesive) were applied based on previous methods 
(Slawecki et al. 2005). Patches (7.17 cm2) cut based on rat weights delivered 5 mg/kg/day. 
The dorsum of the head was shaved for placement with re-applications occurring once daily 
for 10 days in adolescence (PD 35-44) or 10 days in adulthood (PD 60-69). For nicotine 
delivered during RAM testing, nicotine hydrogen tartrate salt (Sigma, St. Louis, MO) was 
dissolved in 0.9% sterile saline to a stock solution of 0.5 mg/ml (expressed as base of the 
salt), adjusted to pH 7.4.
Cognitive Testing
Contextual-spatial learning and working memory were assessed and recorded in real time 
(blind to lesion status and nicotine history) using an 8-arm RAM. The RAM (Med 
Associates, St. Albans, VT) stood 6.5 cm above the floor with an octagonal arena (29.5 cm 
diameter) and eight runways extending radially (61cm × 9cm × 17 cm walls), surrounded by 
visual landmarks. At the beginning of all sessions, a food reward (½ Kellogg's Froot Loop) 
was placed at the end of all 8 arms, behind a wall 7 cm from the end of each runway, 
requiring rats to traverse each arm entirely to discover and consume the food reward. After 
initiating food-restriction (limited so that rats would never drop below 85% of their pre-test 
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weights) one day before testing, rats were tested over 15 sessions, one session per day. In 
each session, rats navigated the maze from a start in the central arena to acquire Froot Loops 
lasting until all arms were entered (all four paws entered) or 300 seconds had expired, 
whichever came first. As rats learn the maze over multiple sessions, they complete the maze 
more efficiently both in terms of making fewer entries into arms already entered for that 
session, and requiring less time to complete. Rats also tend to consume more Froot loops 
over learning, although in normal rats, maze performance (e.g. ETR) can often exceed the 
number of Froot loops consumed, as some Froot loops may be found but left uneaten. 
Parameters of contextual-spatial working memory performance and attention to the task 
(efficiency) were quantified as Entries to Repeat (ETR; number of arms entered before an 
arm entry was repeated), and total Session Time. The number of Froot Loops eaten was also 
recorded as a dependent measure that provides an indication of natural reward consumption, 
(while understanding that rats could not eat more rewards than the number of arms they 
enter, and that normal rats do not always eat all the rewards they encounter. This measure is 
also useful for verifying that poor maze performance that could occur is not merely a result 
of lack of normal motivation to find and consume the food. To see if acute nicotine delivery 
could differentially impact cognitive performance, based on lesion status and prior chronic 
nicotine history, all subjects received a behaviorally active dose of nicotine (0.5 mg/kg s.c.) 
(Berg and Chambers 2008; Berg et al. 2013) 30 minutes before the final 3 sessions.
Receptor Binding and Lesion Verification
Rats were sacrificed under isoflourane and decapitated. Three 2 mm coronal sections, 
starting at the frontal pole, were cut with a Brinkman chopper from harvested brains. The 
medial prefrontal cortex (MPFC) was micro-dissected from the second section (Swanson 
2004) while the nucleus accumbens (NAC), caudate-putamen (CAPU), and somatosensory 
cortex (ssCTX) were micro-dissected from the third (Figure 1A). Samples were bilaterally 
pooled and stored (−80 °C).
The binding protocol using [3H]-epibatidine (2 nM) began with sample homogenization 
with Tissue Tearor (Model 985-370, Biospec Products, Inc) in 50 mM Tris-HCl buffer, pH 
7.4, at room temperature. The homogenate was centrifuged twice with a Beckman Model 
J2-21 Centrifuge at 4 °C and 35,000 × g for 10 minutes in fresh buffer. Pellets were re-
suspended in fresh buffer and added to tubes containing Tris buffer and [3H]-epibatidine (2 
nM) with or without 300 μM nicotine to a final incubation volume of 1 ml. Samples 
incubated for 2 hours at room temperature. Binding was terminated by filtration through 
GF/C glass fiber filters presoaked in 0.5% polyethylenimine to reduce nonspecific binding. 
Samples were then washed three times with ice-cold distilled water. The filters were placed 
in vials and counted with a scintillation counter. Nonspecific binding was determined in the 
presence of nicotine. Specific binding was calculated by subtracting nonspecific from total 
binding. All samples were run in duplicate with results averaged.
Brains were evaluated for appropriate lesions as described previously (Chambers and Lipska 
2011), blind from behavioral results and prior to binding. Caudal brains containing the 
hippocampus were cryostat-cut into 40 μm coronal sections every 400 μm from 
approximately 3.3 to −5.8 mm (bregma), then fixed and stained with 0.5% thionin. Damage 
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was assessed microscopically as tissue atrophy, paucity of nuclei, or cellular disarray in the 
ventral hippocampus. Brains with unilateral damage, damage extending into the dorsal 
hippocampus, or into medial or lateral structures were excluded from analysis. Exemplary 
histologies of rats included in the study are shown in Figure 1B (Swanson 2004). For RAM-
testing, 34 SHAMs and 40 lesions were initially prepared, with 34 (85%) having acceptable 
lesions. For binding, 37 SHAMs and 46 lesions were initially prepared with 37 of lesions 
(80%) qualifying. Thus at total of N =142 rats were analyzed in the study with n=68 rats 
entering the cognitive arm and n=74 entering binding. In the receptor binding analysis that 
compared rat and analogous human data, only adult rats (n=35) were examined.
Statistics
For RAM testing, dependent measures (ETR, Session time, Froot Loops) were analyzed 
across the first 4 time blocks (with each block being an average of 3 consecutive once-daily 
sessions) to assess initial learning. Subsequently, these measures were examined across 
blocks 4-5 to assess acute effects of nicotine pre-injections. Four-way Repeated Measures 
ANOVAs examined lesion, age, and drug history over blocks. Post hoc analyses using 
smaller dimensional ANOVAs investigated key interactions. For binding, 3-way ANOVAs 
(lesion, age, drug history) were applied to receptor densities in regions separately. 
Additional 2-way ANOVAs of brain regions replicating analyses conducted in recent 
neuroimaging of α4β2 receptors in human were also performed (Esterlis et al. 2014). For this 
analysis, we examined adult rats only, and 2 brain regions (ventral striatum, MPFC), which 
corresponded to subject ages and brain regions examined in the human study (Esterlis et al 
also examined thalamus, parietal cortex and hippocampus, which we did not). Data are 
presented as means + SEM throughout text and figures, with significance at p<0.05.
RESULTS
Cognition
Across the first 4 blocks of RAM experience, rats demonstrated learning with increasing 
ETR (block: F(3,180)=18.48, p<0.001) (Figure 2A, 2B), although NVHL showed 
impairments (lesion: F(1, 60)=9.19, p<0.01) with a nearly significant interaction between 
lesion and block (F(3,180)=2.5, p=0.06). Although nicotine history had no stand-alone main 
effect to change ETR, it did alter the shape of the learning curve (block × drug: 
F(3,180)=2.77, p<0.05), flattening it somewhat, in an age-dependent way (block × age × 
drug: F(3, 180)=2.846, p<0.05) (Figure 2A, 2B). Post hoc testing (2-way ANOVAs: age × 
drug) at each block revealed this as significant effects of age (F(1,64)=4.47, p<0.05) and 
drug (F(1,64)=7.86, p<0.01) (Figure 2C) in the first block, with relatively better 
performance (increased ETR) immediately after nicotine exposure (in the first block) 
particularly in adolescents. Rats also increased maze performance efficiency as session 
times decreased overall (blocks: F(3, 180)=109.66, p<0.001) (Figure 2D, 2E), with 
adolescent and SHAM rats showing steeper learning curves compared to their adult (block × 
age: F(3, 180)=7.41, p<0.001) and NVHL counterparts (block × lesion: F(3, 180)=5.21, 
p<0.01). The latter interaction is more clearly visible in post-hoc ANOVAs of lesion effects 
at each block (Figure 2F), showing that NVHL rats were increasingly less efficient 
compared to SHAMS as learning progressed over the sessions reaching significance in the 
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4th block (lesion: (F(1,66)= 7.59, p<0.01)). Time per arm entered, as a more sensitive 
measure of non-specific locomotor speed on the maze (compared to session time), also 
decreased across the 4 blocks (F(3,180)=15.87, p<0.001). However, unlike session time, 
time per arm did not vary by lesion, age or nicotine history, indicating that the effects on 
session time were not due merely to non-specific changes in locomotor speed.
Food-Reward Consumption
RAM learning over the first 4 blocks produced overall increases in Froot Loop consumption 
(blocks: F(3, 180)=110.06, p<0.001) (Figure 2G, 2H). Adolescents consumed greater 
amounts both in the earlier sessions (block × age: F(3, 180)=9.38, p<0.001) and overall (age: 
F(1, 60)=26.63, p<0.001); 5.52 ±.27/session compared to 3.45± .36 for adults. NVHL rats 
also showed greater consumption (F(1, 60)=11.65, p<0.01), consuming 5.12 ±.29 Froot 
Loops/session compared to 3.86±.39 for SHAMs, showing that their cognitive performance 
deficits (in terms of ETR and Session time) could not be accounted for as reflecting lack of 
reward motivation. As with NVHL effects, nicotine history also increased consumption 
(F(1, 60)=15.48, p<0.001), so that nicotine-exposed rats consumed 5.23±.33 per session 
compared to 3.65±.35 for PBO rats. A three way interaction of main effects was detected 
(F(1, 60)=5.74, p<0.05) prompting post hoc 2-way ANOVAs at each age looking at lesion 
and drug effects on average Froot Loops consumed (Figure 2I). NVHLs increased 
consumption in both adolescents (F(1,30)=5.94, p<0.05 ) and adults F(1,30)=6.49, p<0.05) 
while in adolescents only, nicotine history increased consumption significantly 
(F(1,30)=25.47, p<0.001), and more so in SHAMs than NVHLs (lesion × drug: 
F(1,30)=6.59, p<0.015)), potentially due to a ceiling effect limiting nicotine history 
increases in NVHLS .
Acute Nicotine Effects on Maze Performance
In observing whether acute nicotine injections delivered 30 minutes before each of block 5 
sessions could further improve cognition, RAM performance was examined as a repeated 
measure from block 4 to 5 (Figure 3). ETR improved overall (block: F(1,60) =12.7, 
p<0.001) while NVHLs remained impaired (lesion: F(1,60) =11.7, p <0.001) without any 
effects or interactions of nicotine history, age, or block (lesion × drug: F(1,60)=0.1, p=0.74, 
lesion × block: F(1,60)=2.0, p=0.16) (Figures 3A, 3B). Session time also shortened (block: 
F(1,60)=53.9, p<0.001), but in a way that did depend on nicotine history (block × drug: 
F(1,60)=4.2, p<0.05) (Figures 3C, 3D). Post-hocs examining nicotine history at each block 
suggested this interaction was carried by an effect of acute nicotine to improve performance 
for rats with nicotine history only (contrast block 4, drug: F(1,66)=0.01, p=0.9 with block 5, 
drug: F(1,66)=3.7, p=0.059). Accordingly, rats with and without nicotine histories had 
almost identical session times in block 4 (154.4 ±9.4 vs. 155.7 ± 10.9) that separated 
substantially in block 5 (108.5±6.5 vs.129.7 ± 9.1). Notably, the performance effect of acute 
nicotine on session time cannot readily be attributed to a locomotor speed (e.g. locomotor 
sensitization) effect of acute nicotine injections in rats with nicotine patch histories, because, 
unlike total session time, average time per arm did not vary significantly as an interaction 
between nicotine patch history and block (F(1,60)=1.13, p=0.30). The effect of acute 
nicotine injections to specifically enhance performance in nicotine patch exposed animals 
compared to non-nicotine exposed, beyond what practice on the maze is producing, is best 
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visualized in Figure 3G which shows session times over all 5 blocks of RAM testing. 
Again, although NVHL deficits in session time were significant (lesion: F(1,60)=9.96, 
p<0.01), acute nicotine effects did not interact with NVHLs to improve session time (lesion 
× drug: F(1,60)= 0.2, p=0.64 and lesion × block: F(1,60)=1.1, p=.30). Acute nicotine also 
did not interact with adolescent age-effects to lower session times (age:(F(1,60)=19, 
p<0.001)). Froot loops consumed also increased across blocks 4 to 5 (F(1,60)=14.6, 
p<0.001) (Figure 3E, 3F), with more consumption by NVHLs (lesion: F(1,60)=6.9, 
p<0.05), but in a way that varied by block (lesion × block: F(1,60)=5.2, p<0.05) suggestive 
of NVHL consumption nearing a ceiling effect.
Receptor Binding
Baseline and nicotine-induced nAChR expression across brain regions are shown Figure 4. 
In the NAC, adolescents showed lower nAChR expression (age: F(1,66)=8.0, p<0.01). Rats 
with nicotine exposure had elevated nAChR densities in the NAC (F(1,66)=25.3, p<0.001) 
(42% increase), CAPU (F(1,66)=23.3, p<0.001) (42% increase), MPFC (F(1,66)=20.0, 
p<0.001) (36% increase) and SSCTX (F(1,66)= 46.1, p<0.001) (73% increase).
Although in 13 out of 16 comparisons (same age/drug history) NVHLs had lower nAChR 
densities vs. SHAMs, lesion effects in the initial 3-way analysis were not significant. There 
also were no significant interactions between nicotine effects and lesion in any region (drug 
× lesion/NAC: F(1,66)=0.02, p=0.89; CAPU: F(1,66)=0.15, p=0.70; MPFC: F(1,66)=0.10, 
p=0.75; SSCTX: F(1,66)= 0.002, p=0.96). However in secondary analyses focusing on 
MPFC and striatal regions in adult rats only, consistent with regions and statistical 
approaches used in recent nAChR imaging in humans (Esterlis et al. 2014) (Figure 5A, 5C), 
NVHLs reduced α4β2 binding (lesion:(F(1,31)=4.7, p<0.05) in the MPFC by 12.1% (Figure 
5B), paralleling 13.8 % decreases in human schizophrenia, without producing significant 
modulation in the ventral striatum ((lesion/NAC: F(1,31)=0.33, p=0.57) (Figure 5D) or 
dorsal striatum (lesion/CAPU: F(1,31)=0.44, p=0.51), where lesion based changes in 
nAChR densities were <5% different from SHAMs. Also consistent with the human data 
(Esterlis et al. 2014), this analysis showed nicotine-induced increases in receptor densities 
across these regions (drug/MPFC: F(1,31)=65, p<0.001; drug/NAC: F(1,31)=33, p<0.001), 
but these nicotine effects did not interact with NVHLs (lesion × drug/MPFC: F(1,33)=0.38, 
p=0.54; lesion × drug/NAC: F(1,33)=0.24, p=0.63).
DISCUSSION
NVHLs show schizophrenia-like deficits in contextual-working memory with prior nicotine 
patch exposure having little impact on subsequent cognition, and no specific effects on the 
cognition of NVHLs vs. controls. Similarly, although acute nicotine injections did have 
some effect to enhance efficiency of maze performance, this effect was specific only to rats 
with prior nicotine history and was not different between NVHLs and SHAMs. Prior chronic 
nicotine history was nevertheless clearly pharmacologically active both behaviorally and 
biologically in SHAM and NVHL rats alike: Nicotine history was just as potent as the 
NVHL in increasing food consumption used to motivate maze learning. Nicotine also 
significantly increased nAChR expression, but again without interacting with NVHL effects 
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on receptor densities. NVHLs produced down-regulation of nAChR densities that reached 
significance in the MPFC, but not in striatal regions. This pattern of results is in tight 
agreement with recent in-vivo neuroimaging of β2-nAChR receptors in schizophrenia 
subjects (Esterlis et al. 2014), which parallel to our own study is the first human study 
published thus far that uses a 2 × 2 design to examine nAChRs in mentally ill vs. healthy 
brains with and without nicotine history. Prior work has shown that nicotine-behavioral 
sensitization, and acquisition, maintenance and relapse phases of nicotine self-administration 
are all amplified in the NVHL model (Berg and Chambers 2008; Berg et al. 2013). Together 
with the present findings where biologically and behaviorally active histories of chronic 
nicotine exposure failed to alter NVHL- cognitive deficits, or abnormal α4β2 receptors 
patterns in a way that is different from healthy rats, these data do not support the self-
medication explanation for increased nicotine use in schizophrenia as mediated by illness-
specific therapeutic changes in cognition or nAChRs.
Multiple studies have now examined the effects of nicotine in NVHL-deficient cognition 
measured on the RAM (Berg et al. 2013; Chambers et al. 1996). Despite differences in 
dosing, routes of entry, and timing of cognitive testing relative to nicotine delivery, whether 
before (Chambers et al. 1996), during (Berg et al. 2013), or after (present study), the same 
result was observed: Schizophrenia-like cognitive deficits are present in the NVHL model, 
but are not uniquely nor substantially ameliorated by nicotine in a way that is different from 
what nicotine does in healthy rats. The present study adds weight to this conclusion by 
showing that while new nicotine dosing (Figure 3) impacts maze performance (session 
time) in subjects with prior nicotine histories, this effect was not NVHL specific. These 
findings agree with recent well-controlled human experiments (that account for baseline 
differences in smoking history) in which schizophrenia smokers vs. controls (non-smoking 
schizophrenia, non-mentally ill smokers, non-mentally ill non-smokers) also do not show 
differential cognitive responses to nicotine challenge delivered via intranasal, transdermal 
patches, or smoking (Hahn et al. 2013; Quisenaerts et al. 2014). Of additional translational 
significance, the present study showed that nicotine history and NVHLs increased 
consumption of the simple carbohydrate reward that baited the maze (Froot Loops). 
Increased appetite and weight gain are well-documented complications of smoking cessation 
in humans (Stamford et al. 1986), and pharmacological modulation of α4β2 receptors alter 
appetitive responses (Cocores and Gold 2008). Likewise, schizophrenia patients have 
heightened obesity risk (McCreadie 2003). Notably, the lack of substantial or specific 
cognitive benefits of nicotine in NVHL rats cannot be interpreted as insensitivity of NVHL 
rats to the pharmacological-behavioral effects of nicotine, because strong appetitive effects 
after cessation of nicotine history were observed in both NVHL and SHAM rats alike. 
Similarly, we saw no differential effects of acute nicotine injections to alter cognition in 
NVHL vs. SHAMs (either in terms of ETR or Session time), even though these injections do 
produce a significantly stronger behavioral locomotor sensitization effect in NVHLs 
compared to SHAMs (Berg and Chambers 2008). Still, more studies are needed to examine 
the cognitive effects of nicotine in alternative schizophrenia models and using cognitive 
paradigms alternative to the RAM to determine the generalizability of these findings. Effects 
of acute nicotine to temporarily improve cognition, uniquely in rats previously exposed to 
nicotine, should also be confirmed with experiments using vehicle injections. In terms of 
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examining the differential effects of nicotine history on cognition due to adolescent vs. adult 
exposure (and their interaction with NVHLs), future studies should advance beyond the 
present study to vary both the developmental timing of nicotine exposure and the timing of 
cognitive testing.
This is the first study of nAChRs in the NVHL model or any other widely validated animal 
model of schizophrenia although abnormal acetylcholinergic neurotransmission has been 
observed in the PFC of NVHL rats after manipulation of dopamine and glutamate 
transmitter systems (Alexander et al. 2009; Laplante et al. 2004a; Laplante et al. 2004b). 
Our results show that while α4β2 receptor densities are not modulated by NVHLs as 
strongly as with nicotine, these receptors are down regulated by NVHLs in the MPFC, but 
not in underlying-striatal regions, closely paralleling human schizophrenia data (Esterlis et 
al. 2014). Since NVHL effects on nAChR receptor down regulation in the MPFC occurred 
as a consequence of early developmental hippocampal lesions in an outbred strain (e.g. 
without pre-selection for a specific genetic background), our results raise the intriguing 
possibility that nAChR expression deficits in schizophrenia may not necessarily depend 
directly or specifically on abnormalities in nAChR genes. Rather, such changes could be 
secondary to cortical-hippocampal disconnection associated with a wide variety of other 
genetic and environmental factors. Accordingly, low brain nAChR densities also occur in 
neuropsychiatric disorders other than schizophrenia, e.g. in patients with non-specific 
cognitive impairments and dementia (Sabri et al. 2008). A wide range of molecular, cellular, 
and architectural abnormalities have been identified in the MPFC of NVHL rats, including 
down regulations in the expression levels of multiple genes(Chambers et al. 2013; Tseng et 
al. 2008). Accordingly, the NVHL-based nAChR reductions we are reporting represent just 
one piece of an extremely complex set of biological changes in the MPFC secondary to the 
early developmental hippocampal insult.
The capacity of chronic nicotine exposure to up-regulate α4β2 nAChR densities we 
observed in the present investigation is a well replicated observation in animals and humans 
(D'Souza et al. 2012; Nguyen et al. 2004) indicating that the chronic dosing of nicotine we 
used was biologically active and appropriate to the research question being pursued. 
Accordingly, we found that nicotine history drove up MPFC and NAC nAChRs by 57% and 
43% in MPFC and NAC regions respectively over baselines found in PBO patch rats. These 
are comparable to 37% and 32% increases in nAChR binding in the PFC and striatum of 
human smokers vs. non-smokers found by Esterlis et al (Esterlis et al. 2014). While 
demonstrating that the NVHL model does emulate human schizophrenia nAChR receptor 
patterns at least in terms of α4β2 and other receptor complexes that epibatidine binds, it 
remains unknown whether certain medications, abused drugs, comorbid disease states, or 
aging could further down-regulate nAChRs in NVHL rats or schizophrenia. Further studies 
using the NVHL model with alternative ligands for α4β2 and α7 receptor complexes are 
needed to investigate these possibilities.
Comparing nicotine effects in adolescents vs. adults tested whether cognitive or receptor 
modulation could depend on adolescent neurodevelopmental changes implicated in 
schizophrenia, addiction, or the NVHL model (Chambers et al. 2003; Weinberger 1987). 
The effects of nicotine history on learning did differ somewhat by age in terms of a three-
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way interaction between block, age, and nicotine on ETR, suggesting nicotine withdrawal 
has different effects in adolescents (O'Dell et al. 2004). However, this effect was subtle as it 
was not observed as a 2-way interaction of age and nicotine in either ETR or session time. 
Meanwhile, nAChRs were also not differentially modulated in any brain region by nicotine 
according to age of exposure. The strongest effects of age on RAM performance emerged as 
adolescent-increases in food consumption, and as adolescent-decreases in overall session 
time in the later RAM sessions. Meanwhile, only one brain region, the NAC, displayed an 
age-related difference of nAChR densities (regardless of nicotine exposure). Altogether, 
these findings do not suggest that nicotine's effects on cognition or nAChRs, in SHAM or 
NVHLs, are particularly dependent on adolescent vs. adult nicotine exposure. However they 
do hint at the possibility of a stronger interplay between adolescent neurodevelopment, 
nAChRs in the NAC, and nicotine's effects on natural appetitive motivation.
In summary, in line with emerging human cognitive and imaging data (Esterlis et al. 2014; 
Hahn et al. 2013; Quisenaerts et al. 2014; Roh et al. 2014) these results do not support 
hypotheses espousing nicotine as a cognitive enhancer that is specifically efficacious for 
schizophrenia compared to healthy brains. Further, these data do not support the idea that 
nicotine-induced up-regulation of nAChR densities occurs differentially in the schizophrenic 
brain as a basis for cognitive remediation, or as a mechanism that increases rates of nicotine 
use, even as MPFC densities of nAChRs are abnormally low in the disorder. NVHL rats 
emulate a wide range of biological and behavioral abnormalities involving prefrontal 
cortical-striatal circuits and altered responsiveness to several types of addictive drugs, that 
are characteristic of both schizophrenia and addicted populations (Chambers et al. 2013; 
Tseng et al. 2009). Here, we determined that although encompassing increased nicotine 
addiction vulnerability behaviors consistent with human schizophrenia, the NVHL model 
does not show differential responsiveness to the cognitive or nicotinic receptor effects of 
nicotine. These findings are in disagreement with widely held assumptions that beneficial-
medicinal effects of nicotine are key to driving up high use rates of this drug in mental 
illness. However, these and related findings in the NVHL model do agree with recent human 
pharmacological and neuroimaging data suggesting that cortical-striatal circuit disturbances 
in schizophrenia generate increased nicotine addiction vulnerability (Moran et al. 2013), 
while the cognitive-benefits of nicotine may be subtle, transient, and not different than in 
healthy brains (Esterlis et al. 2014; Hahn et al. 2013; Quisenaerts et al. 2014; Roh et al. 
2014). More animal and human studies that focus on mechanisms of addiction pathogenesis 
that are shared among addictive drugs, and accelerated in the context of mental illness, are 
needed for developing more effective prevention and treatment strategies for dual diagnosis 
disorders including schizophrenia.
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Figure 1. Experimental Design and Histology
(A) Experimental arms and time lines according to post natal days (PD) of adolescent vs. 
adult NIC vs. PBO patch exposure are shown with final experiment subgroups numbers (N). 
Tussue for nAChR binding was dissected according to cortical-striatal regions shown at 
lower right. (B) Left panels depict smallest (white) and largest extents (black) of 
hippocampal changes in NVHL rats (n=71) included in the study. Photomicrographs (right) 
show NVHL vs. SHAM brains illustrating optimal NVHL damage at the confluence of 
ventral and dorsal blades of the hippocampus (arrows). Section maps and coordinates 
relative to Bregma based on Swanson(Swanson 2004).
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Figure 2. Cognitive testing
ETR (A, B) Session time (D, E) and Froot loops Eaten (G, H) were analyzed separately 
using mixed ANOVAs (lesion, drug patch history, age, blocks) with age sorted into columns 
for visual clarity only. Statistical effects are presented at right of the (B) column (*p<0.05, 
**p<0.01, ***p<0.001, NS=non-significant), with post-hoc graphs and ANOVAs and 
exploring specific interactions (indicated by rightward arrows) shown in (C) column. In (C), 
age and drug history effects were examined at each block; in (F), lesion at each block; in (I), 
mean Froot Loops consumed over all blocks, were examined as effects of lesion and drug 
history for each age group. Subgroup numbers (n) shown below (I) are accurate to all 
panels.
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Figure 3. Cognitive performance with acute nicotine pre-injections
Block 4 to 5 performance on ETR (A, B), Session time (C, D) and Froot Loops Eaten (E, F) 
analyzed as mixed ANOVAs (lesion, drug patch history, age, blocks) is shown with ages 
sorted into columns for visual clarity. Significant main effects or interactions are presented 
on the right (*p<0.05, **p<0.01, ***p<0.001). In (G), data for all rats (n=68) is compiled 
according to NIC vs. PBO patch history groupings only, depicting the nicotine history 
specificity of acute nicotine pre-injections to improve Session time in NIC patch history rats 
only, as per the block × drug interaction in (D).
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Figure 4. nAChR binding densities
The 4 cortical striatal regions were analyzed in separate 3-way ANOVAs (lesion, drug 
history, age) with ages parsed into left and right columns for visual clarity. Significant 
effects are presented at right (**p<0.01, ***p<0.001). Subgroup numbers (n) are accurate to 
all panels in the figure.
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Figure 5. nAChR binding densities in adult rats in NAC and MPFC
A comparison of α4β2 densities in human (in vivo imaging) (Esterlis et al. 2014) (A, C) vs 
(present rat data) (D, E) focuses on comparable regions, ages and analytic approach (2-way 
ANOVA (schizophrenia vs. nicotine histories). Control Non-smokers (CNS) compare with 
SHAM-PBO; Schizophrenia Non-smokers (SczNS) with NVHL-PBO; Control Smokers 
(CS) with SHAM-NIC; and Schizophrenia Smokers (SczS) with NVHL- NIC. Subgroup n's 
for the respective human and animal studies are depicted at bottom.
Berg et al. Page 19
Psychopharmacology (Berl). Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
